Novartis reports US approval for Cosentyx in polymyalgia rheumatica
Novartis said on 17 November that the US Food and Drug Administration had approved Cosentyx, also called secukinumab, for certain adults with polymyalgia rheumatica. The indication covers adults whose response to corticosteroids is inadequate or who cannot tolerate corticosteroid tapering.

Edivro Company News · Original attributed summary. Source announcement: 2026-11-17.
Novartis said on 17 November that the US Food and Drug Administration had approved Cosentyx, also called secukinumab, for certain adults with polymyalgia rheumatica. The indication covers adults whose response to corticosteroids is inadequate or who cannot tolerate corticosteroid tapering.
Novartis said this was the drug’s eleventh approved US indication. The company said the same condition was already covered by an EU approval, while regulatory review continued in other markets including Japan.
Which US patients does the new indication cover?
It covers the adult patient groups specified in the approval, as described by Novartis.
Questions about this story
These answers summarise the article and refer to its original reporting period.
Which US patients does the new indication cover?
It covers the adult patient groups specified in the approval, as described by Novartis.
What is the main development in this story?
Novartis said on 17 November that the US Food and Drug Administration had approved Cosentyx, also called secukinumab, for certain adults with polymyalgia rheumatica. The indication covers adults whose response to corticosteroids is inadequate or who cannot tolerate corticosteroid tapering.
Publisher
Edivro Editorial


